B7-H3 targeted CAR-T therapy(CellabMED)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameB7-H3 targeted CAR-T therapy(CellabMED)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCD276 antigen modulators

TargetsCD276 antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCellabMED Inc

China Registration ClassN/A

Develop Information

Active CompaniesCellabMED Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A